Compare ZBH & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZBH | RVMD |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 15.2B |
| IPO Year | N/A | 2020 |
| Metric | ZBH | RVMD |
|---|---|---|
| Price | $87.78 | $118.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 16 |
| Target Price | ★ $107.40 | $95.44 |
| AVG Volume (30 Days) | 2.0M | ★ 4.8M |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.03 | N/A |
| Revenue | ★ $8,010,900,000.00 | N/A |
| Revenue This Year | $7.98 | N/A |
| Revenue Next Year | $5.16 | $714.57 |
| P/E Ratio | $21.71 | ★ N/A |
| Revenue Growth | ★ 5.47 | N/A |
| 52 Week Low | $85.33 | $29.17 |
| 52 Week High | $114.44 | $124.49 |
| Indicator | ZBH | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 77.17 |
| Support Level | $85.83 | $113.96 |
| Resistance Level | $89.00 | $124.49 |
| Average True Range (ATR) | 2.80 | 6.94 |
| MACD | -0.41 | 1.26 |
| Stochastic Oscillator | 20.72 | 88.66 |
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.